Revised recommendations for RSV immunisation in infants and toddlers, with earlier and broader protective measures, aim to combat an expected surge in cases during the upcoming season, urging families and providers to plan ahead amid shifting seasonality and geographic variations.
Parents heading into the 2026-27 RSV season are being asked to make decisions earlier than they might have a few years ago, because the prevention playbook has widened again. On September 2, the American Academy of Pediatrics said it was expanding the list of high-risk young children who should be offered RSV immunisation for a second season. Meanwhile, a North Carolina public-health memo issued on July 23 set out the operational timetable already being used by providers: maternal RSV vaccination from September 1, 2026 to January 31, 2027, and infant antibody products from October 1, 2026 to March 31, 2027.
For most families, the choice is no longer simply how to respond if a baby becomes unwell, but how to protect that baby before RSV is widely circulating. The CDC says most infants need one of two forms of protection against severe disease, not both: vaccination during pregnancy with Pfizer’s Abrysvo, or a long-acting antibody given to the baby after birth. The agency now lists two antibody products for infants, nirsevimab and clesrovimab. In most of the continental United States, the CDC says antibody protection for babies is given during October through March, with the best timing either shortly before the season begins or, for babies born during that window, within the first week of life, ideally during the birth hospital stay.
That makes timing especially important for pregnant patients in late summer and autumn. The Society for Maternal-Fetal Medicine says Abrysvo is the only RSV vaccine approved for use in pregnancy and recommends it at 32 through 36 weeks, typically between September 1 and January 31 in most parts of the United States, so long as delivery is not expected within the next two weeks. The group also adds a point many parents may not know: if a patient already received the maternal RSV vaccine in a previous pregnancy, a repeat dose is not advised in a later pregnancy because there are no efficacy data for repeated use. In that situation, the baby should instead receive a monoclonal antibody after birth.
The advice for older babies and toddlers is narrower, but it has become more active this month. The CDC says some children aged 8 to 19 months who are entering their second RSV season should receive nirsevimab if they are at increased risk of severe disease. That group includes children with chronic lung disease of prematurity who needed recent medical support, those with severe immunocompromise, certain children with cystic fibrosis, and American Indian or Alaska Native children. AAP News reported that the academy has now broadened the high-risk category further for the 2026-27 season and has updated its immunisation schedule and dosing guides to match. It also noted that RSV remains the leading cause of infant hospitalisation in the United States and is linked to about 50,000 to 80,000 hospitalisations each year in children under 5.
Why does this matter so much to families with newborns? Mayo Clinic says RSV is so common that most children have had it by age 2, and in older children and adults it often looks much like an ordinary cold. The danger is concentrated in the youngest babies, especially premature infants and children with heart or lung disease. Mayo notes that RSV can spread to the lower respiratory tract and cause bronchiolitis or pneumonia, and that severe or life-threatening infection requiring hospital care can occur in premature infants or in people with chronic heart or lung problems.
Parents should also know what worsening illness looks like. Mayo Clinic says severe RSV in infants can bring short, shallow and rapid breathing, visible pulling-in of the chest muscles and skin with each breath, poor feeding, unusual tiredness and irritability. In more serious cases, it notes, babies and children may develop difficulty breathing and a bluish colour caused by lack of oxygen. The clinic advises seeking immediate medical attention if a child has breathing difficulty, a high fever or blue discolouration, especially on the lips or nail beds.
Seasonality is another area where the simple national message only goes so far. The CDC says the standard October-to-March timing applies to most of the continental United States, but it also tells providers that RSV activity varies by geography and that state or territorial health authorities may shift the timing earlier or later. The agency specifically flags tropical climates and places with less predictable circulation, while Mayo Clinic says the typical US season is November through March but can differ in Florida, Alaska, Hawaii, Puerto Rico, Guam and Pacific island territories. In other words, parents should treat the national calendar as a guide, not a guarantee.
The practical message for September 2026 is that families with a baby due soon, or with an infant who has not yet had RSV protection arranged, should not wait for local outbreaks to fill the news. North Carolina’s health department told providers that orders for Abrysvo, Beyfortus and Enflonsia opened on August 3 and said it did not expect shortages this season, although doses are still distributed through monthly CDC allocations. Combined with the new AAP update and the CDC’s advice to give protection as early in the eligible window as possible, that suggests the most useful conversation for parents this month is not about home remedies after infection, but about which prevention route fits their child before RSV becomes a fixture of the autumn and winter clinic queue.
Disclaimer: This content is for informational purposes only and is not intended to be a substitute for professional medical judgment, advice, diagnosis, or treatment.
